Sign in

    Dave Windley • Jefferies LLC

    Dave Windley's questions to STERIS plc (STE) leadership

    Dave Windley's questions to STERIS plc (STE) leadership • Q1 2026

    Question

    Dave Windley of Jefferies LLC inquired about hospital clients' views on the impact of potential healthcare policy changes on procedure volumes and asked for clarification on the company's foreign exchange (FX) hedging strategy.

    Answer

    Daniel Carestio, President & CEO, conveyed that potential policy changes are viewed by customers as a reimbursement challenge rather than a demand issue, noting that procedure volumes and capital orders remain strong. Michael Tokich, Senior VP & CFO, explained that the company is largely naturally hedged, with the bottom-line impact of favorable FX expected to be offset by higher tariff costs in the current forecast.

    Ask Fintool Equity Research AI

    Dave Windley's questions to Certara Inc (CERT) leadership

    Dave Windley's questions to Certara Inc (CERT) leadership • Q2 2025

    Question

    Dave Windley of Jefferies LLC asked about the signs that a client is on the cusp of a steeper adoption curve for biosimulation, particularly for NAMs, and whether clients are using Simcyp in a new way to replace animal models.

    Answer

    CEO William Feehery explained that adoption often begins with a services project before moving to software. Regarding NAMs, he noted that many customers were already modeling monoclonal antibodies in parallel with animal testing for other benefits, like dose optimization. The FDA's guidance is now allowing them to leverage this existing work to reduce animal use.

    Ask Fintool Equity Research AI

    Dave Windley's questions to Oscar Health Inc (OSCR) leadership

    Dave Windley's questions to Oscar Health Inc (OSCR) leadership • Q2 2025

    Question

    Dave Windley from Jefferies asked about the profile of new members gained in 2025 and how Oscar is getting comfortable that market morbidity won't continue to deteriorate as program integrity efforts remove certain members from the market.

    Answer

    CFO Scott Blackley responded that membership strength was driven by both strong retention and SEP growth, with new members showing MLR profiles consistent with historical patterns. He stated that since program integrity rules for 2025 are already in effect and they have not seen a significant shift in their low-utilizer population, they do not see signals of further market morbidity deterioration.

    Ask Fintool Equity Research AI

    Dave Windley's questions to Stevanato Group SpA (STVN) leadership

    Dave Windley's questions to Stevanato Group SpA (STVN) leadership • Q2 2025

    Question

    Dave Windley of Jefferies LLC asked for quantification of the growth contribution from GLP-1s and inquired about the drivers of margin improvement, specifically the balance between a richer product mix versus improved plant utilization.

    Answer

    CEO Franco Stevanato explained that while GLP-1s are a significant long-term tailwind, the company categorizes them under the broader Biologics umbrella, which grew to 39% of BDS revenue. CFO Marco Dal Lago attributed margin improvement to both higher volumes and a favorable mix shift towards high-performance products like Nexa syringes.

    Ask Fintool Equity Research AI

    Dave Windley's questions to Humana Inc (HUM) leadership

    Dave Windley's questions to Humana Inc (HUM) leadership • Q2 2025

    Question

    Dave Windley of Jefferies LLC asked for a reminder of Humana's medical and pharmacy cost trend assumptions for 2025 and its initial outlook for 2026.

    Answer

    CFO Celeste Mellet reiterated that the company expects low double-digit pharmacy trends and mid-to-high single-digit medical cost trends for 2025. She stated that the expectations for 2026 are consistent with these figures.

    Ask Fintool Equity Research AI

    Dave Windley's questions to Centene Corp (CNC) leadership

    Dave Windley's questions to Centene Corp (CNC) leadership • Q2 2025

    Question

    Dave Windley of Jefferies LLC asked about the implications of the Wakely data on the total Marketplace size, seeking Centene's assumptions on further membership attrition and the corresponding morbidity shift for the remainder of 2025.

    Answer

    CEO Sarah London stated that the Wakely data indicated lower-than-expected market growth and that Centene believes the market contracted during open enrollment. She projected Centene's own Marketplace membership would decline from 5.9 million to 5.4 million by year-end, driven partly by 'Failure to Report' (FTR) impacts, and confirmed this attrition is factored into their morbidity assumptions.

    Ask Fintool Equity Research AI

    Dave Windley's questions to Centene Corp (CNC) leadership • Q2 2025

    Question

    Dave Windley of Jefferies LLC asked about the implications of the Wakely data on Marketplace membership trends, specifically inquiring about the current market size and Centene's assumptions for attrition and morbidity shifts for the remainder of the year.

    Answer

    CEO Sarah London stated that the Wakely data indicated lower market growth than previously estimated, suggesting the market contracted during open enrollment. For Centene, she projected membership would decline from 5.9 million to 5.4 million by year-end, driven partly by 'Failure to Report' (FTR) impacts. This expected attrition and any related morbidity shifts are factored into the company's updated forecast.

    Ask Fintool Equity Research AI

    Dave Windley's questions to Medpace Holdings Inc (MEDP) leadership

    Dave Windley's questions to Medpace Holdings Inc (MEDP) leadership • Q2 2025

    Question

    Dave Windley from Jefferies LLC asked for a breakdown of the increased revenue guidance between pass-through costs and direct revenue, questioned how Medpace is achieving higher productivity, and inquired about hiring plans and the biotech funding environment.

    Answer

    CFO Kevin Brady confirmed that accelerated reimbursable costs are a large driver of the revenue guidance increase, but noted the EBITDA guide was also raised due to greater productivity from factors like improved attrition. CEO August Troendle acknowledged the weak public funding data but expressed confidence for the year based on their internal pipeline, provided cancellations remain low.

    Ask Fintool Equity Research AI